Amneal Q3 revenue beats estimates on affordable medicines growth; outlook raised
AMRX•Amneal’s third-quarter revenue rose 10% to $863 million and adjusted EPS increased 53% to $0.26, both beating estimates. The company raised its 2026 revenue, adjusted EBITDA and adjusted EPS guidance.
1. Quarterly results
Amneal reported third-quarter revenue of $863 million, up 10% year over year and above the $815.86 million analyst estimate. Adjusted EPS rose 53% to $0.26, also beating the $0.23 estimate; net loss was $22 million and adjusted EBITDA was $207 million.
2. Growth and outlook
Revenue from Affordable Medicines rose 19%, driven by biosimilars, women’s health patches and new launches. Specialty net revenue increased 20%, led by CREXONT, BREKIYA autoinjector and UNITHROID, while AvKARE revenue fell 17%. Amneal raised 2026 revenue guidance to $3.15 billion-$3.25 billion, adjusted EBITDA guidance to $800 million-$815 million and adjusted diluted EPS guidance to $1.04-$1.08.
